On 11 September 2019 Advocate General Hogan issued his Opinion in connection with the combined referrals to the CJEU in Royalty Pharma C-650/17 and Sandoz C-114/18. Both referrals concern the interpretation of Article 3(a) of the SPC Regulation, which requires that:

"A[n SPC] shall be granted if...    the product is protected by a basic patent in force"

If the CJEU adopt the Advocate General's advice it would represent a further tightening of the interpretation of Article 3(a), with a trend towards excluding SPC protection based on a patent which does not individually disclose the active ingredient(s) of an authorised product.  This would arguably introduce a bar on grant of an SPC from a basic patent relating to early-stage fundamental research, as opposed to later-stage clinical development work.

Read our analysis of the Opinion here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.